SYEDA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SYEDA (SYEDA).
Syeda is a combination of drospirenone and ethinyl estradiol, a contraceptive that suppresses gonadotropins, primarily inhibiting ovulation; drospirenone has antimineralocorticoid and antiandrogenic activity.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4; drospirenone is metabolized by CYP3A4 and to a lesser extent by CYP1A1 and CYP2C19. |
| Excretion | Urinary excretion (40-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for 15-25%. |
| Half-life | Terminal elimination half-life of 12-15 hours; allows twice-daily dosing for sustained therapeutic levels. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: within minutes. |
| Duration of Action | 12-24 hours; clinical effect wanes with drug clearance. |
1 tablet (3 mg drospirenone / 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with severe renal impairment (CrCl <30 mL/min). For mild to moderate impairment (CrCl 30-50 mL/min), use with caution; monitor potassium levels due to drospirenone's antimineralocorticoid effect. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. For postmenarchal adolescents, dosing is same as adult: 1 tablet orally once daily for 21 days, then 7 days placebo. |
| Geriatric use | Not indicated for use in postmenopausal women. No geriatric-specific dosing guidelines; use is inappropriate in this population. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SYEDA (SYEDA).
| Breastfeeding | Present in breast milk; M/P ratio not reported. Not recommended during breastfeeding due to potential adverse effects on infant development and hormonal disruption. Use alternative contraception if breastfeeding. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: high risk of neural tube defects, cardiac anomalies, and cleft palate. Second and third trimesters: risk of fetal adrenal suppression, virilization of female fetuses if androgenic progestins are present. Contraindicated in pregnancy due to teratogenicity and fetal harm. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day), particularly in women over 35. Women over 35 who smoke should not use combination oral contraceptives.
| Serious Effects |
Renal impairment, adrenal insufficiency, hepatic disease, high risk of thromboembolic disorders, cerebrovascular or coronary artery disease, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, known or suspected pregnancy, undiagnosed abnormal uterine bleeding, current or past breast cancer or other estrogen-sensitive neoplasia, liver tumors, and hypersensitivity to any component.
| Precautions | Thromboembolic disorders and other vascular events, cardiovascular disease, liver disease, hypertension, gallbladder disease, carbohydrate and lipid metabolism effects, headache, bleeding irregularities, depression, and use in women with hereditary angioedema. |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of pregnancy if sexually active; perform pregnancy test before initiation and monthly. Monitor for thromboembolic events, hypertension, depression, and liver dysfunction. Fetal monitoring not applicable as drug is contraindicated in pregnancy. |
| Fertility Effects | Suppresses ovulation; intended for contraception. Reversible upon discontinuation. No permanent effects on fertility, but may delay return to ovulation post therapy. |